Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Caribou Biosciences (CRBU) Equity Average (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Equity Average for 6 consecutive years, with $154.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average fell 47.95% to $154.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $154.0 million, a 47.95% decrease, with the full-year FY2024 number at $310.7 million, down 7.16% from a year prior.
  • Equity Average was $154.0 million for Q3 2025 at Caribou Biosciences, down from $191.7 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $396.1 million in Q4 2021 to a low of -$41.7 million in Q2 2021.
  • A 5-year average of $263.1 million and a median of $295.8 million in 2024 define the central range for Equity Average.
  • Biggest YoY gain for Equity Average was 2497.89% in 2021; the steepest drop was 1346.31% in 2021.
  • Caribou Biosciences' Equity Average stood at $396.1 million in 2021, then fell by 21.11% to $312.5 million in 2022, then grew by 22.67% to $383.3 million in 2023, then crashed by 30.33% to $267.1 million in 2024, then crashed by 42.34% to $154.0 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Equity Average are $154.0 million (Q3 2025), $191.7 million (Q2 2025), and $235.1 million (Q1 2025).